Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-08-01

Clinical Trial Update: Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for valbenazine evaluating its efficacy, safety, and tolerability for dyskinesia associated with cerebral palsy; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INGREZZA (valbenazine)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Dyskinesia, Cerebral Palsy | Phase 3 | Status: ACTIVE_NOT_RECRUITING